nodes	percent_of_prediction	percent_of_DWPC	metapath
Cevimeline—CYP3A4—Estropipate—osteoporosis	0.0664	0.158	CbGbCtD
Cevimeline—CYP3A4—Calcitriol—osteoporosis	0.0664	0.158	CbGbCtD
Cevimeline—CYP2D6—Cholecalciferol—osteoporosis	0.0538	0.128	CbGbCtD
Cevimeline—CYP3A4—Ergocalciferol—osteoporosis	0.0531	0.126	CbGbCtD
Cevimeline—CYP3A4—Raloxifene—osteoporosis	0.0443	0.105	CbGbCtD
Cevimeline—CYP3A4—Ethinyl Estradiol—osteoporosis	0.0428	0.102	CbGbCtD
Cevimeline—CYP3A4—Cholecalciferol—osteoporosis	0.0342	0.0814	CbGbCtD
Cevimeline—CYP3A4—Conjugated Estrogens—osteoporosis	0.0314	0.0748	CbGbCtD
Cevimeline—CYP3A4—Estradiol—osteoporosis	0.0276	0.0656	CbGbCtD
Cevimeline—Anorexia—Pamidronate—osteoporosis	0.0002	0.000355	CcSEcCtD
Cevimeline—Chest pain—Zoledronate—osteoporosis	0.0002	0.000354	CcSEcCtD
Cevimeline—Arthralgia—Zoledronate—osteoporosis	0.0002	0.000354	CcSEcCtD
Cevimeline—Myalgia—Zoledronate—osteoporosis	0.0002	0.000354	CcSEcCtD
Cevimeline—Palpitations—Conjugated Estrogens—osteoporosis	0.0002	0.000354	CcSEcCtD
Cevimeline—Insomnia—Risedronate—osteoporosis	0.0002	0.000354	CcSEcCtD
Cevimeline—Anxiety—Zoledronate—osteoporosis	0.000199	0.000353	CcSEcCtD
Cevimeline—Loss of consciousness—Conjugated Estrogens—osteoporosis	0.000199	0.000352	CcSEcCtD
Cevimeline—Paraesthesia—Risedronate—osteoporosis	0.000198	0.000351	CcSEcCtD
Cevimeline—Pruritus—Estropipate—osteoporosis	0.000198	0.00035	CcSEcCtD
Cevimeline—Discomfort—Zoledronate—osteoporosis	0.000198	0.00035	CcSEcCtD
Cevimeline—Asthenia—Alendronate—osteoporosis	0.000197	0.00035	CcSEcCtD
Cevimeline—Hypersensitivity—Ibandronate—osteoporosis	0.000197	0.00035	CcSEcCtD
Cevimeline—Cough—Conjugated Estrogens—osteoporosis	0.000197	0.00035	CcSEcCtD
Cevimeline—Dyspnoea—Risedronate—osteoporosis	0.000197	0.000349	CcSEcCtD
Cevimeline—Hypotension—Pamidronate—osteoporosis	0.000196	0.000348	CcSEcCtD
Cevimeline—Convulsion—Conjugated Estrogens—osteoporosis	0.000196	0.000347	CcSEcCtD
Cevimeline—Fatigue—Ethinyl Estradiol—osteoporosis	0.000195	0.000346	CcSEcCtD
Cevimeline—Pruritus—Alendronate—osteoporosis	0.000195	0.000345	CcSEcCtD
Cevimeline—Dyspepsia—Risedronate—osteoporosis	0.000194	0.000344	CcSEcCtD
Cevimeline—Eye disorder—Estradiol—osteoporosis	0.000194	0.000344	CcSEcCtD
Cevimeline—Tinnitus—Estradiol—osteoporosis	0.000194	0.000344	CcSEcCtD
Cevimeline—Constipation—Ethinyl Estradiol—osteoporosis	0.000194	0.000343	CcSEcCtD
Cevimeline—Confusional state—Zoledronate—osteoporosis	0.000193	0.000343	CcSEcCtD
Cevimeline—Hypersensitivity—Calcitriol—osteoporosis	0.000193	0.000342	CcSEcCtD
Cevimeline—Cardiac disorder—Estradiol—osteoporosis	0.000193	0.000342	CcSEcCtD
Cevimeline—Flushing—Estradiol—osteoporosis	0.000193	0.000342	CcSEcCtD
Cevimeline—Arthralgia—Conjugated Estrogens—osteoporosis	0.000193	0.000341	CcSEcCtD
Cevimeline—Myalgia—Conjugated Estrogens—osteoporosis	0.000193	0.000341	CcSEcCtD
Cevimeline—Chest pain—Conjugated Estrogens—osteoporosis	0.000193	0.000341	CcSEcCtD
Cevimeline—Asthenia—Ibandronate—osteoporosis	0.000192	0.000341	CcSEcCtD
Cevimeline—Anxiety—Conjugated Estrogens—osteoporosis	0.000192	0.00034	CcSEcCtD
Cevimeline—Nausea—Etidronic acid—osteoporosis	0.000192	0.00034	CcSEcCtD
Cevimeline—Oedema—Zoledronate—osteoporosis	0.000192	0.00034	CcSEcCtD
Cevimeline—Musculoskeletal discomfort—Pamidronate—osteoporosis	0.000191	0.000339	CcSEcCtD
Cevimeline—Diarrhoea—Estropipate—osteoporosis	0.000191	0.000339	CcSEcCtD
Cevimeline—Infection—Zoledronate—osteoporosis	0.00019	0.000338	CcSEcCtD
Cevimeline—Fatigue—Risedronate—osteoporosis	0.00019	0.000337	CcSEcCtD
Cevimeline—Insomnia—Pamidronate—osteoporosis	0.00019	0.000336	CcSEcCtD
Cevimeline—Pruritus—Ibandronate—osteoporosis	0.00019	0.000336	CcSEcCtD
Cevimeline—Pain—Risedronate—osteoporosis	0.000189	0.000335	CcSEcCtD
Cevimeline—Constipation—Risedronate—osteoporosis	0.000189	0.000335	CcSEcCtD
Cevimeline—Angiopathy—Estradiol—osteoporosis	0.000189	0.000334	CcSEcCtD
Cevimeline—Shock—Zoledronate—osteoporosis	0.000189	0.000334	CcSEcCtD
Cevimeline—Paraesthesia—Pamidronate—osteoporosis	0.000188	0.000334	CcSEcCtD
Cevimeline—Diarrhoea—Alendronate—osteoporosis	0.000188	0.000334	CcSEcCtD
Cevimeline—Asthenia—Calcitriol—osteoporosis	0.000188	0.000333	CcSEcCtD
Cevimeline—Nervous system disorder—Zoledronate—osteoporosis	0.000188	0.000333	CcSEcCtD
Cevimeline—Thrombocytopenia—Zoledronate—osteoporosis	0.000188	0.000333	CcSEcCtD
Cevimeline—Dyspnoea—Pamidronate—osteoporosis	0.000187	0.000332	CcSEcCtD
Cevimeline—Tachycardia—Zoledronate—osteoporosis	0.000187	0.000332	CcSEcCtD
Cevimeline—Feeling abnormal—Ethinyl Estradiol—osteoporosis	0.000187	0.000331	CcSEcCtD
Cevimeline—Chills—Estradiol—osteoporosis	0.000187	0.000331	CcSEcCtD
Cevimeline—Somnolence—Pamidronate—osteoporosis	0.000187	0.000331	CcSEcCtD
Cevimeline—Skin disorder—Zoledronate—osteoporosis	0.000186	0.00033	CcSEcCtD
Cevimeline—Pruritus—Calcitriol—osteoporosis	0.000186	0.000329	CcSEcCtD
Cevimeline—Hyperhidrosis—Zoledronate—osteoporosis	0.000185	0.000328	CcSEcCtD
Cevimeline—Gastrointestinal pain—Ethinyl Estradiol—osteoporosis	0.000185	0.000328	CcSEcCtD
Cevimeline—Diarrhoea—Raloxifene—osteoporosis	0.000185	0.000328	CcSEcCtD
Cevimeline—Dyspepsia—Pamidronate—osteoporosis	0.000185	0.000327	CcSEcCtD
Cevimeline—Dizziness—Estropipate—osteoporosis	0.000185	0.000327	CcSEcCtD
Cevimeline—Oedema—Conjugated Estrogens—osteoporosis	0.000185	0.000327	CcSEcCtD
Cevimeline—Alopecia—Estradiol—osteoporosis	0.000184	0.000326	CcSEcCtD
Cevimeline—Infection—Conjugated Estrogens—osteoporosis	0.000183	0.000325	CcSEcCtD
Cevimeline—Diarrhoea—Ibandronate—osteoporosis	0.000183	0.000325	CcSEcCtD
Cevimeline—Anorexia—Zoledronate—osteoporosis	0.000183	0.000324	CcSEcCtD
Cevimeline—Decreased appetite—Pamidronate—osteoporosis	0.000182	0.000323	CcSEcCtD
Cevimeline—Dizziness—Alendronate—osteoporosis	0.000182	0.000322	CcSEcCtD
Cevimeline—Shock—Conjugated Estrogens—osteoporosis	0.000182	0.000322	CcSEcCtD
Cevimeline—Nervous system disorder—Conjugated Estrogens—osteoporosis	0.000181	0.000321	CcSEcCtD
Cevimeline—Malnutrition—Estradiol—osteoporosis	0.000181	0.000321	CcSEcCtD
Cevimeline—Fatigue—Pamidronate—osteoporosis	0.000181	0.000321	CcSEcCtD
Cevimeline—Gastrointestinal pain—Risedronate—osteoporosis	0.000181	0.00032	CcSEcCtD
Cevimeline—Tachycardia—Conjugated Estrogens—osteoporosis	0.00018	0.000319	CcSEcCtD
Cevimeline—Urticaria—Ethinyl Estradiol—osteoporosis	0.00018	0.000319	CcSEcCtD
Cevimeline—Pain—Pamidronate—osteoporosis	0.000179	0.000318	CcSEcCtD
Cevimeline—Constipation—Pamidronate—osteoporosis	0.000179	0.000318	CcSEcCtD
Cevimeline—Diarrhoea—Calcitriol—osteoporosis	0.000179	0.000318	CcSEcCtD
Cevimeline—Skin disorder—Conjugated Estrogens—osteoporosis	0.000179	0.000318	CcSEcCtD
Cevimeline—Hypotension—Zoledronate—osteoporosis	0.000179	0.000317	CcSEcCtD
Cevimeline—Abdominal pain—Ethinyl Estradiol—osteoporosis	0.000179	0.000317	CcSEcCtD
Cevimeline—Body temperature increased—Ethinyl Estradiol—osteoporosis	0.000179	0.000317	CcSEcCtD
Cevimeline—Dizziness—Raloxifene—osteoporosis	0.000179	0.000317	CcSEcCtD
Cevimeline—Hyperhidrosis—Conjugated Estrogens—osteoporosis	0.000178	0.000316	CcSEcCtD
Cevimeline—Flatulence—Estradiol—osteoporosis	0.000178	0.000316	CcSEcCtD
Cevimeline—Vomiting—Estropipate—osteoporosis	0.000178	0.000315	CcSEcCtD
Cevimeline—Dysgeusia—Estradiol—osteoporosis	0.000177	0.000314	CcSEcCtD
Cevimeline—Dizziness—Ibandronate—osteoporosis	0.000177	0.000314	CcSEcCtD
Cevimeline—Rash—Estropipate—osteoporosis	0.000176	0.000312	CcSEcCtD
Cevimeline—Dermatitis—Estropipate—osteoporosis	0.000176	0.000312	CcSEcCtD
Cevimeline—Anorexia—Conjugated Estrogens—osteoporosis	0.000176	0.000312	CcSEcCtD
Cevimeline—Urticaria—Risedronate—osteoporosis	0.000175	0.000311	CcSEcCtD
Cevimeline—Back pain—Estradiol—osteoporosis	0.000175	0.00031	CcSEcCtD
Cevimeline—Headache—Estropipate—osteoporosis	0.000175	0.00031	CcSEcCtD
Cevimeline—Vomiting—Alendronate—osteoporosis	0.000175	0.00031	CcSEcCtD
Cevimeline—Musculoskeletal discomfort—Zoledronate—osteoporosis	0.000175	0.00031	CcSEcCtD
Cevimeline—Abdominal pain—Risedronate—osteoporosis	0.000175	0.000309	CcSEcCtD
Cevimeline—Body temperature increased—Risedronate—osteoporosis	0.000175	0.000309	CcSEcCtD
Cevimeline—Muscle spasms—Estradiol—osteoporosis	0.000174	0.000308	CcSEcCtD
Cevimeline—Rash—Alendronate—osteoporosis	0.000173	0.000307	CcSEcCtD
Cevimeline—Insomnia—Zoledronate—osteoporosis	0.000173	0.000307	CcSEcCtD
Cevimeline—Dermatitis—Alendronate—osteoporosis	0.000173	0.000307	CcSEcCtD
Cevimeline—Feeling abnormal—Pamidronate—osteoporosis	0.000173	0.000307	CcSEcCtD
Cevimeline—Hypotension—Conjugated Estrogens—osteoporosis	0.000172	0.000306	CcSEcCtD
Cevimeline—Headache—Alendronate—osteoporosis	0.000172	0.000305	CcSEcCtD
Cevimeline—Paraesthesia—Zoledronate—osteoporosis	0.000172	0.000305	CcSEcCtD
Cevimeline—Vomiting—Raloxifene—osteoporosis	0.000172	0.000305	CcSEcCtD
Cevimeline—Gastrointestinal pain—Pamidronate—osteoporosis	0.000172	0.000304	CcSEcCtD
Cevimeline—Dyspnoea—Zoledronate—osteoporosis	0.000171	0.000303	CcSEcCtD
Cevimeline—Rash—Raloxifene—osteoporosis	0.000171	0.000302	CcSEcCtD
Cevimeline—Dermatitis—Raloxifene—osteoporosis	0.00017	0.000302	CcSEcCtD
Cevimeline—Somnolence—Zoledronate—osteoporosis	0.00017	0.000302	CcSEcCtD
Cevimeline—Vomiting—Ibandronate—osteoporosis	0.00017	0.000302	CcSEcCtD
Cevimeline—Tremor—Estradiol—osteoporosis	0.00017	0.000301	CcSEcCtD
Cevimeline—Headache—Raloxifene—osteoporosis	0.00017	0.0003	CcSEcCtD
Cevimeline—Rash—Ibandronate—osteoporosis	0.000169	0.000299	CcSEcCtD
Cevimeline—Dermatitis—Ibandronate—osteoporosis	0.000169	0.000299	CcSEcCtD
Cevimeline—Dyspepsia—Zoledronate—osteoporosis	0.000169	0.000299	CcSEcCtD
Cevimeline—Musculoskeletal discomfort—Conjugated Estrogens—osteoporosis	0.000168	0.000298	CcSEcCtD
Cevimeline—Ill-defined disorder—Estradiol—osteoporosis	0.000168	0.000298	CcSEcCtD
Cevimeline—Headache—Ibandronate—osteoporosis	0.000168	0.000297	CcSEcCtD
Cevimeline—Insomnia—Conjugated Estrogens—osteoporosis	0.000167	0.000296	CcSEcCtD
Cevimeline—Hypersensitivity—Ethinyl Estradiol—osteoporosis	0.000167	0.000296	CcSEcCtD
Cevimeline—Vomiting—Calcitriol—osteoporosis	0.000167	0.000296	CcSEcCtD
Cevimeline—Decreased appetite—Zoledronate—osteoporosis	0.000167	0.000295	CcSEcCtD
Cevimeline—Agitation—Estradiol—osteoporosis	0.000166	0.000295	CcSEcCtD
Cevimeline—Nausea—Estropipate—osteoporosis	0.000166	0.000294	CcSEcCtD
Cevimeline—Abdominal pain—Pamidronate—osteoporosis	0.000166	0.000294	CcSEcCtD
Cevimeline—Body temperature increased—Pamidronate—osteoporosis	0.000166	0.000294	CcSEcCtD
Cevimeline—Paraesthesia—Conjugated Estrogens—osteoporosis	0.000166	0.000294	CcSEcCtD
Cevimeline—Rash—Calcitriol—osteoporosis	0.000165	0.000293	CcSEcCtD
Cevimeline—Fatigue—Zoledronate—osteoporosis	0.000165	0.000293	CcSEcCtD
Cevimeline—Dermatitis—Calcitriol—osteoporosis	0.000165	0.000293	CcSEcCtD
Cevimeline—Dyspnoea—Conjugated Estrogens—osteoporosis	0.000165	0.000292	CcSEcCtD
Cevimeline—Headache—Calcitriol—osteoporosis	0.000164	0.000291	CcSEcCtD
Cevimeline—Somnolence—Conjugated Estrogens—osteoporosis	0.000164	0.000291	CcSEcCtD
Cevimeline—Pain—Zoledronate—osteoporosis	0.000164	0.000291	CcSEcCtD
Cevimeline—Constipation—Zoledronate—osteoporosis	0.000164	0.000291	CcSEcCtD
Cevimeline—Nausea—Alendronate—osteoporosis	0.000163	0.00029	CcSEcCtD
Cevimeline—Malaise—Estradiol—osteoporosis	0.000163	0.000289	CcSEcCtD
Cevimeline—Hypersensitivity—Risedronate—osteoporosis	0.000163	0.000288	CcSEcCtD
Cevimeline—Vertigo—Estradiol—osteoporosis	0.000163	0.000288	CcSEcCtD
Cevimeline—Dyspepsia—Conjugated Estrogens—osteoporosis	0.000162	0.000288	CcSEcCtD
Cevimeline—Asthenia—Ethinyl Estradiol—osteoporosis	0.000162	0.000288	CcSEcCtD
Cevimeline—Syncope—Estradiol—osteoporosis	0.000162	0.000288	CcSEcCtD
Cevimeline—Nausea—Raloxifene—osteoporosis	0.000161	0.000285	CcSEcCtD
Cevimeline—Decreased appetite—Conjugated Estrogens—osteoporosis	0.00016	0.000284	CcSEcCtD
Cevimeline—Pruritus—Ethinyl Estradiol—osteoporosis	0.00016	0.000284	CcSEcCtD
Cevimeline—Palpitations—Estradiol—osteoporosis	0.00016	0.000284	CcSEcCtD
Cevimeline—Fatigue—Conjugated Estrogens—osteoporosis	0.000159	0.000282	CcSEcCtD
Cevimeline—Nausea—Ibandronate—osteoporosis	0.000159	0.000282	CcSEcCtD
Cevimeline—Loss of consciousness—Estradiol—osteoporosis	0.000159	0.000282	CcSEcCtD
Cevimeline—Asthenia—Risedronate—osteoporosis	0.000158	0.000281	CcSEcCtD
Cevimeline—Feeling abnormal—Zoledronate—osteoporosis	0.000158	0.00028	CcSEcCtD
Cevimeline—Cough—Estradiol—osteoporosis	0.000158	0.00028	CcSEcCtD
Cevimeline—Pain—Conjugated Estrogens—osteoporosis	0.000158	0.00028	CcSEcCtD
Cevimeline—Constipation—Conjugated Estrogens—osteoporosis	0.000158	0.00028	CcSEcCtD
Cevimeline—Gastrointestinal pain—Zoledronate—osteoporosis	0.000157	0.000278	CcSEcCtD
Cevimeline—Hypertension—Estradiol—osteoporosis	0.000156	0.000277	CcSEcCtD
Cevimeline—Pruritus—Risedronate—osteoporosis	0.000156	0.000277	CcSEcCtD
Cevimeline—Nausea—Calcitriol—osteoporosis	0.000156	0.000276	CcSEcCtD
Cevimeline—Diarrhoea—Ethinyl Estradiol—osteoporosis	0.000155	0.000275	CcSEcCtD
Cevimeline—Hypersensitivity—Pamidronate—osteoporosis	0.000155	0.000274	CcSEcCtD
Cevimeline—Chest pain—Estradiol—osteoporosis	0.000154	0.000273	CcSEcCtD
Cevimeline—Arthralgia—Estradiol—osteoporosis	0.000154	0.000273	CcSEcCtD
Cevimeline—Myalgia—Estradiol—osteoporosis	0.000154	0.000273	CcSEcCtD
Cevimeline—Anxiety—Estradiol—osteoporosis	0.000154	0.000272	CcSEcCtD
Cevimeline—Urticaria—Zoledronate—osteoporosis	0.000152	0.00027	CcSEcCtD
Cevimeline—Discomfort—Estradiol—osteoporosis	0.000152	0.00027	CcSEcCtD
Cevimeline—Abdominal pain—Zoledronate—osteoporosis	0.000152	0.000269	CcSEcCtD
Cevimeline—Body temperature increased—Zoledronate—osteoporosis	0.000152	0.000269	CcSEcCtD
Cevimeline—Diarrhoea—Risedronate—osteoporosis	0.000151	0.000268	CcSEcCtD
Cevimeline—Gastrointestinal pain—Conjugated Estrogens—osteoporosis	0.000151	0.000268	CcSEcCtD
Cevimeline—Asthenia—Pamidronate—osteoporosis	0.000151	0.000267	CcSEcCtD
Cevimeline—Dizziness—Ethinyl Estradiol—osteoporosis	0.00015	0.000265	CcSEcCtD
Cevimeline—Confusional state—Estradiol—osteoporosis	0.000149	0.000264	CcSEcCtD
Cevimeline—Pruritus—Pamidronate—osteoporosis	0.000148	0.000263	CcSEcCtD
Cevimeline—Oedema—Estradiol—osteoporosis	0.000148	0.000262	CcSEcCtD
Cevimeline—Infection—Estradiol—osteoporosis	0.000147	0.00026	CcSEcCtD
Cevimeline—Urticaria—Conjugated Estrogens—osteoporosis	0.000147	0.00026	CcSEcCtD
Cevimeline—Dizziness—Risedronate—osteoporosis	0.000146	0.000259	CcSEcCtD
Cevimeline—Body temperature increased—Conjugated Estrogens—osteoporosis	0.000146	0.000259	CcSEcCtD
Cevimeline—Abdominal pain—Conjugated Estrogens—osteoporosis	0.000146	0.000259	CcSEcCtD
Cevimeline—Shock—Estradiol—osteoporosis	0.000145	0.000258	CcSEcCtD
Cevimeline—Nervous system disorder—Estradiol—osteoporosis	0.000145	0.000257	CcSEcCtD
Cevimeline—Tachycardia—Estradiol—osteoporosis	0.000144	0.000256	CcSEcCtD
Cevimeline—Vomiting—Ethinyl Estradiol—osteoporosis	0.000144	0.000255	CcSEcCtD
Cevimeline—Diarrhoea—Pamidronate—osteoporosis	0.000144	0.000254	CcSEcCtD
Cevimeline—Skin disorder—Estradiol—osteoporosis	0.000144	0.000254	CcSEcCtD
Cevimeline—Hyperhidrosis—Estradiol—osteoporosis	0.000143	0.000253	CcSEcCtD
Cevimeline—Rash—Ethinyl Estradiol—osteoporosis	0.000143	0.000253	CcSEcCtD
Cevimeline—Dermatitis—Ethinyl Estradiol—osteoporosis	0.000143	0.000253	CcSEcCtD
Cevimeline—Headache—Ethinyl Estradiol—osteoporosis	0.000142	0.000251	CcSEcCtD
Cevimeline—Hypersensitivity—Zoledronate—osteoporosis	0.000141	0.00025	CcSEcCtD
Cevimeline—Vomiting—Risedronate—osteoporosis	0.00014	0.000249	CcSEcCtD
Cevimeline—Rash—Risedronate—osteoporosis	0.000139	0.000247	CcSEcCtD
Cevimeline—Dermatitis—Risedronate—osteoporosis	0.000139	0.000246	CcSEcCtD
Cevimeline—Dizziness—Pamidronate—osteoporosis	0.000139	0.000246	CcSEcCtD
Cevimeline—Headache—Risedronate—osteoporosis	0.000138	0.000245	CcSEcCtD
Cevimeline—Asthenia—Zoledronate—osteoporosis	0.000138	0.000244	CcSEcCtD
Cevimeline—Hypersensitivity—Conjugated Estrogens—osteoporosis	0.000136	0.000241	CcSEcCtD
Cevimeline—Pruritus—Zoledronate—osteoporosis	0.000136	0.00024	CcSEcCtD
Cevimeline—Musculoskeletal discomfort—Estradiol—osteoporosis	0.000135	0.000239	CcSEcCtD
Cevimeline—Nausea—Ethinyl Estradiol—osteoporosis	0.000135	0.000238	CcSEcCtD
Cevimeline—Insomnia—Estradiol—osteoporosis	0.000134	0.000237	CcSEcCtD
Cevimeline—Vomiting—Pamidronate—osteoporosis	0.000133	0.000236	CcSEcCtD
Cevimeline—Paraesthesia—Estradiol—osteoporosis	0.000133	0.000235	CcSEcCtD
Cevimeline—Asthenia—Conjugated Estrogens—osteoporosis	0.000132	0.000235	CcSEcCtD
Cevimeline—Rash—Pamidronate—osteoporosis	0.000132	0.000235	CcSEcCtD
Cevimeline—Dermatitis—Pamidronate—osteoporosis	0.000132	0.000234	CcSEcCtD
Cevimeline—Dyspnoea—Estradiol—osteoporosis	0.000132	0.000233	CcSEcCtD
Cevimeline—Headache—Pamidronate—osteoporosis	0.000131	0.000233	CcSEcCtD
Cevimeline—Somnolence—Estradiol—osteoporosis	0.000131	0.000233	CcSEcCtD
Cevimeline—Diarrhoea—Zoledronate—osteoporosis	0.000131	0.000232	CcSEcCtD
Cevimeline—Nausea—Risedronate—osteoporosis	0.000131	0.000232	CcSEcCtD
Cevimeline—Pruritus—Conjugated Estrogens—osteoporosis	0.000131	0.000231	CcSEcCtD
Cevimeline—Dyspepsia—Estradiol—osteoporosis	0.00013	0.00023	CcSEcCtD
Cevimeline—Decreased appetite—Estradiol—osteoporosis	0.000128	0.000228	CcSEcCtD
Cevimeline—Fatigue—Estradiol—osteoporosis	0.000127	0.000226	CcSEcCtD
Cevimeline—Dizziness—Zoledronate—osteoporosis	0.000127	0.000225	CcSEcCtD
Cevimeline—Pain—Estradiol—osteoporosis	0.000126	0.000224	CcSEcCtD
Cevimeline—Constipation—Estradiol—osteoporosis	0.000126	0.000224	CcSEcCtD
Cevimeline—Diarrhoea—Conjugated Estrogens—osteoporosis	0.000126	0.000224	CcSEcCtD
Cevimeline—Nausea—Pamidronate—osteoporosis	0.000125	0.000221	CcSEcCtD
Cevimeline—Dizziness—Conjugated Estrogens—osteoporosis	0.000122	0.000216	CcSEcCtD
Cevimeline—Vomiting—Zoledronate—osteoporosis	0.000122	0.000216	CcSEcCtD
Cevimeline—Feeling abnormal—Estradiol—osteoporosis	0.000122	0.000216	CcSEcCtD
Cevimeline—Rash—Zoledronate—osteoporosis	0.000121	0.000214	CcSEcCtD
Cevimeline—Gastrointestinal pain—Estradiol—osteoporosis	0.000121	0.000214	CcSEcCtD
Cevimeline—Dermatitis—Zoledronate—osteoporosis	0.000121	0.000214	CcSEcCtD
Cevimeline—Headache—Zoledronate—osteoporosis	0.00012	0.000213	CcSEcCtD
Cevimeline—Vomiting—Conjugated Estrogens—osteoporosis	0.000117	0.000208	CcSEcCtD
Cevimeline—Urticaria—Estradiol—osteoporosis	0.000117	0.000208	CcSEcCtD
Cevimeline—Abdominal pain—Estradiol—osteoporosis	0.000117	0.000207	CcSEcCtD
Cevimeline—Body temperature increased—Estradiol—osteoporosis	0.000117	0.000207	CcSEcCtD
Cevimeline—Rash—Conjugated Estrogens—osteoporosis	0.000116	0.000206	CcSEcCtD
Cevimeline—Dermatitis—Conjugated Estrogens—osteoporosis	0.000116	0.000206	CcSEcCtD
Cevimeline—Headache—Conjugated Estrogens—osteoporosis	0.000116	0.000205	CcSEcCtD
Cevimeline—Nausea—Zoledronate—osteoporosis	0.000114	0.000202	CcSEcCtD
Cevimeline—Nausea—Conjugated Estrogens—osteoporosis	0.00011	0.000194	CcSEcCtD
Cevimeline—Hypersensitivity—Estradiol—osteoporosis	0.000109	0.000193	CcSEcCtD
Cevimeline—Asthenia—Estradiol—osteoporosis	0.000106	0.000188	CcSEcCtD
Cevimeline—Pruritus—Estradiol—osteoporosis	0.000105	0.000185	CcSEcCtD
Cevimeline—Diarrhoea—Estradiol—osteoporosis	0.000101	0.000179	CcSEcCtD
Cevimeline—Dizziness—Estradiol—osteoporosis	9.77e-05	0.000173	CcSEcCtD
Cevimeline—CHRM1—GPCR ligand binding—CALCR—osteoporosis	9.52e-05	0.00606	CbGpPWpGaD
Cevimeline—CHRM3—GPCR ligand binding—PTH1R—osteoporosis	9.49e-05	0.00604	CbGpPWpGaD
Cevimeline—CHRM3—GPCR ligand binding—CALCR—osteoporosis	9.49e-05	0.00604	CbGpPWpGaD
Cevimeline—CYP3A4—Phase 1 - Functionalization of compounds—CYP27A1—osteoporosis	9.4e-05	0.00599	CbGpPWpGaD
Cevimeline—Vomiting—Estradiol—osteoporosis	9.39e-05	0.000166	CcSEcCtD
Cevimeline—FMO1—Metabolism—IDH2—osteoporosis	9.34e-05	0.00595	CbGpPWpGaD
Cevimeline—CYP2D6—Cytochrome P450 - arranged by substrate type—CYP19A1—osteoporosis	9.32e-05	0.00594	CbGpPWpGaD
Cevimeline—Rash—Estradiol—osteoporosis	9.32e-05	0.000165	CcSEcCtD
Cevimeline—Dermatitis—Estradiol—osteoporosis	9.31e-05	0.000165	CcSEcCtD
Cevimeline—Headache—Estradiol—osteoporosis	9.26e-05	0.000164	CcSEcCtD
Cevimeline—CYP2D6—Oxidation by Cytochrome P450—CYP19A1—osteoporosis	9.2e-05	0.00586	CbGpPWpGaD
Cevimeline—FMO1—Metabolism—CYP27A1—osteoporosis	8.78e-05	0.0056	CbGpPWpGaD
Cevimeline—Nausea—Estradiol—osteoporosis	8.78e-05	0.000156	CcSEcCtD
Cevimeline—FMO1—Metabolism—ACP5—osteoporosis	8.54e-05	0.00544	CbGpPWpGaD
Cevimeline—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—osteoporosis	8.39e-05	0.00534	CbGpPWpGaD
Cevimeline—CHRM3—Integration of energy metabolism—ADCY5—osteoporosis	8.2e-05	0.00522	CbGpPWpGaD
Cevimeline—FMO1—Metabolism—TPI1—osteoporosis	7.94e-05	0.00506	CbGpPWpGaD
Cevimeline—CYP2D6—Biological oxidations—CYP27A1—osteoporosis	7.64e-05	0.00487	CbGpPWpGaD
Cevimeline—CYP2D6—Phase 1 - Functionalization of compounds—CYP19A1—osteoporosis	7.55e-05	0.00481	CbGpPWpGaD
Cevimeline—CYP3A4—Tryptophan metabolism—CYP19A1—osteoporosis	7.54e-05	0.0048	CbGpPWpGaD
Cevimeline—CYP2D6—Metapathway biotransformation—CYP27A1—osteoporosis	7.53e-05	0.0048	CbGpPWpGaD
Cevimeline—CHRM1—GPCRs, Class A Rhodopsin-like—CNR2—osteoporosis	7.47e-05	0.00476	CbGpPWpGaD
Cevimeline—FMO1—Metabolism—P4HB—osteoporosis	7.47e-05	0.00476	CbGpPWpGaD
Cevimeline—CHRM3—GPCRs, Class A Rhodopsin-like—CNR2—osteoporosis	7.44e-05	0.00474	CbGpPWpGaD
Cevimeline—FMO1—Metabolism—GAPDH—osteoporosis	7.33e-05	0.00467	CbGpPWpGaD
Cevimeline—FMO1—Metabolism—RAP1A—osteoporosis	7.14e-05	0.00455	CbGpPWpGaD
Cevimeline—CHRM1—Class A/1 (Rhodopsin-like receptors)—CNR2—osteoporosis	6.4e-05	0.00408	CbGpPWpGaD
Cevimeline—CHRM3—Class A/1 (Rhodopsin-like receptors)—CNR2—osteoporosis	6.38e-05	0.00406	CbGpPWpGaD
Cevimeline—CHRM1—Calcium Regulation in the Cardiac Cell—ADCY5—osteoporosis	6.17e-05	0.00393	CbGpPWpGaD
Cevimeline—CHRM3—Calcium Regulation in the Cardiac Cell—ADCY5—osteoporosis	6.15e-05	0.00392	CbGpPWpGaD
Cevimeline—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP19A1—osteoporosis	6.09e-05	0.00388	CbGpPWpGaD
Cevimeline—CYP3A4—Oxidation by Cytochrome P450—CYP19A1—osteoporosis	6.01e-05	0.00383	CbGpPWpGaD
Cevimeline—FMO1—Metabolism—ENO1—osteoporosis	5.77e-05	0.00368	CbGpPWpGaD
Cevimeline—FMO1—Metabolism—PSMA5—osteoporosis	5.69e-05	0.00362	CbGpPWpGaD
Cevimeline—FMO1—Metabolism—PSMA2—osteoporosis	5.69e-05	0.00362	CbGpPWpGaD
Cevimeline—CYP2D6—Cytochrome P450 - arranged by substrate type—POMC—osteoporosis	5.6e-05	0.00357	CbGpPWpGaD
Cevimeline—CHRM1—GPCR downstream signaling—CALCR—osteoporosis	5.38e-05	0.00343	CbGpPWpGaD
Cevimeline—CHRM1—GPCR downstream signaling—PTH1R—osteoporosis	5.38e-05	0.00343	CbGpPWpGaD
Cevimeline—CHRM3—GPCR downstream signaling—PTH1R—osteoporosis	5.36e-05	0.00342	CbGpPWpGaD
Cevimeline—CHRM3—GPCR downstream signaling—CALCR—osteoporosis	5.36e-05	0.00342	CbGpPWpGaD
Cevimeline—CHRM1—GPCR ligand binding—PTH—osteoporosis	5e-05	0.00319	CbGpPWpGaD
Cevimeline—CYP3A4—Biological oxidations—CYP27A1—osteoporosis	4.99e-05	0.00318	CbGpPWpGaD
Cevimeline—CHRM3—GPCR ligand binding—PTH—osteoporosis	4.98e-05	0.00318	CbGpPWpGaD
Cevimeline—CYP3A4—Phase 1 - Functionalization of compounds—CYP19A1—osteoporosis	4.94e-05	0.00315	CbGpPWpGaD
Cevimeline—CYP3A4—Metapathway biotransformation—CYP27A1—osteoporosis	4.93e-05	0.00314	CbGpPWpGaD
Cevimeline—CHRM1—Signaling by GPCR—CALCR—osteoporosis	4.88e-05	0.00311	CbGpPWpGaD
Cevimeline—CHRM1—Signaling by GPCR—PTH1R—osteoporosis	4.88e-05	0.00311	CbGpPWpGaD
Cevimeline—CHRM1—GPCR ligand binding—CNR2—osteoporosis	4.87e-05	0.0031	CbGpPWpGaD
Cevimeline—CHRM3—Signaling by GPCR—PTH1R—osteoporosis	4.87e-05	0.0031	CbGpPWpGaD
Cevimeline—CHRM3—Signaling by GPCR—CALCR—osteoporosis	4.87e-05	0.0031	CbGpPWpGaD
Cevimeline—CHRM3—GPCR ligand binding—CNR2—osteoporosis	4.86e-05	0.00309	CbGpPWpGaD
Cevimeline—FMO1—Metabolism—CYP19A1—osteoporosis	4.61e-05	0.00294	CbGpPWpGaD
Cevimeline—CHRM1—GPCR ligand binding—WNT1—osteoporosis	4.58e-05	0.00292	CbGpPWpGaD
Cevimeline—CHRM3—GPCR ligand binding—WNT1—osteoporosis	4.57e-05	0.00291	CbGpPWpGaD
Cevimeline—CYP2D6—Phase 1 - Functionalization of compounds—POMC—osteoporosis	4.54e-05	0.00289	CbGpPWpGaD
Cevimeline—CHRM1—GPCR downstream signaling—MGLL—osteoporosis	4.27e-05	0.00272	CbGpPWpGaD
Cevimeline—CHRM3—GPCR downstream signaling—MGLL—osteoporosis	4.26e-05	0.00271	CbGpPWpGaD
Cevimeline—CHRM1—Circadian rythm related genes—LEP—osteoporosis	4.16e-05	0.00265	CbGpPWpGaD
Cevimeline—CHRM1—GPCR ligand binding—PTHLH—osteoporosis	4.14e-05	0.00264	CbGpPWpGaD
Cevimeline—CHRM3—GPCR ligand binding—PTHLH—osteoporosis	4.13e-05	0.00263	CbGpPWpGaD
Cevimeline—CYP2D6—Biological oxidations—CYP19A1—osteoporosis	4.01e-05	0.00256	CbGpPWpGaD
Cevimeline—CYP2D6—Metapathway biotransformation—CYP19A1—osteoporosis	3.96e-05	0.00252	CbGpPWpGaD
Cevimeline—CHRM1—Signaling by GPCR—MGLL—osteoporosis	3.88e-05	0.00247	CbGpPWpGaD
Cevimeline—CHRM3—Signaling by GPCR—MGLL—osteoporosis	3.87e-05	0.00246	CbGpPWpGaD
Cevimeline—CHRM3—Metabolism—FDPS—osteoporosis	3.8e-05	0.00242	CbGpPWpGaD
Cevimeline—CHRM3—Metabolism—PKM—osteoporosis	3.8e-05	0.00242	CbGpPWpGaD
Cevimeline—FMO1—Metabolism—ADCY5—osteoporosis	3.77e-05	0.0024	CbGpPWpGaD
Cevimeline—FMO1—Metabolism—GPX1—osteoporosis	3.76e-05	0.00239	CbGpPWpGaD
Cevimeline—CYP3A4—Cytochrome P450 - arranged by substrate type—POMC—osteoporosis	3.66e-05	0.00233	CbGpPWpGaD
Cevimeline—CHRM1—GPCR ligand binding—CALCA—osteoporosis	3.65e-05	0.00232	CbGpPWpGaD
Cevimeline—CHRM3—GPCR ligand binding—CALCA—osteoporosis	3.64e-05	0.00232	CbGpPWpGaD
Cevimeline—CHRM3—Metabolism—PGLS—osteoporosis	3.61e-05	0.0023	CbGpPWpGaD
Cevimeline—CHRM3—Metabolism—GPD2—osteoporosis	3.61e-05	0.0023	CbGpPWpGaD
Cevimeline—FMO1—Metabolism—MTHFR—osteoporosis	3.47e-05	0.00221	CbGpPWpGaD
Cevimeline—CHRM1—Gastrin-CREB signalling pathway via PKC and MAPK—IL6R—osteoporosis	3.3e-05	0.0021	CbGpPWpGaD
Cevimeline—CHRM3—Metabolism—ATIC—osteoporosis	3.3e-05	0.0021	CbGpPWpGaD
Cevimeline—CHRM3—Metabolism—PNP—osteoporosis	3.3e-05	0.0021	CbGpPWpGaD
Cevimeline—CHRM3—Gastrin-CREB signalling pathway via PKC and MAPK—IL6R—osteoporosis	3.29e-05	0.0021	CbGpPWpGaD
Cevimeline—CHRM1—Signaling Pathways—SOST—osteoporosis	3.19e-05	0.00203	CbGpPWpGaD
Cevimeline—CHRM3—Signaling Pathways—SOST—osteoporosis	3.18e-05	0.00203	CbGpPWpGaD
Cevimeline—CYP3A4—Phase 1 - Functionalization of compounds—POMC—osteoporosis	2.97e-05	0.00189	CbGpPWpGaD
Cevimeline—CHRM1—Signaling Pathways—CALCR—osteoporosis	2.89e-05	0.00184	CbGpPWpGaD
Cevimeline—CHRM1—Signaling Pathways—PTH1R—osteoporosis	2.89e-05	0.00184	CbGpPWpGaD
Cevimeline—CHRM3—Signaling Pathways—CALCR—osteoporosis	2.88e-05	0.00183	CbGpPWpGaD
Cevimeline—CHRM3—Signaling Pathways—PTH1R—osteoporosis	2.88e-05	0.00183	CbGpPWpGaD
Cevimeline—CHRM1—GPCR downstream signaling—PTH—osteoporosis	2.83e-05	0.0018	CbGpPWpGaD
Cevimeline—CHRM3—GPCR downstream signaling—PTH—osteoporosis	2.82e-05	0.00179	CbGpPWpGaD
Cevimeline—CHRM3—Metabolism—OXCT1—osteoporosis	2.8e-05	0.00179	CbGpPWpGaD
Cevimeline—CHRM3—Metabolism—CA2—osteoporosis	2.8e-05	0.00179	CbGpPWpGaD
Cevimeline—FMO1—Metabolism—POMC—osteoporosis	2.77e-05	0.00177	CbGpPWpGaD
Cevimeline—CHRM1—GPCR downstream signaling—CNR2—osteoporosis	2.75e-05	0.00175	CbGpPWpGaD
Cevimeline—CHRM3—GPCR downstream signaling—CNR2—osteoporosis	2.74e-05	0.00175	CbGpPWpGaD
Cevimeline—CHRM3—Metabolism—MGLL—osteoporosis	2.73e-05	0.00174	CbGpPWpGaD
Cevimeline—CYP3A4—Biological oxidations—CYP19A1—osteoporosis	2.62e-05	0.00167	CbGpPWpGaD
Cevimeline—CYP3A4—Metapathway biotransformation—CYP19A1—osteoporosis	2.59e-05	0.00165	CbGpPWpGaD
Cevimeline—CHRM1—Signaling by GPCR—PTH—osteoporosis	2.57e-05	0.00163	CbGpPWpGaD
Cevimeline—CHRM3—Signaling by GPCR—PTH—osteoporosis	2.56e-05	0.00163	CbGpPWpGaD
Cevimeline—CHRM1—Class A/1 (Rhodopsin-like receptors)—POMC—osteoporosis	2.51e-05	0.0016	CbGpPWpGaD
Cevimeline—CHRM1—Signaling by GPCR—CNR2—osteoporosis	2.5e-05	0.00159	CbGpPWpGaD
Cevimeline—CHRM3—Class A/1 (Rhodopsin-like receptors)—POMC—osteoporosis	2.5e-05	0.00159	CbGpPWpGaD
Cevimeline—CHRM3—Signaling by GPCR—CNR2—osteoporosis	2.49e-05	0.00159	CbGpPWpGaD
Cevimeline—CYP2D6—Biological oxidations—POMC—osteoporosis	2.41e-05	0.00154	CbGpPWpGaD
Cevimeline—CHRM1—Signaling by GPCR—WNT1—osteoporosis	2.35e-05	0.0015	CbGpPWpGaD
Cevimeline—CHRM3—Signaling by GPCR—WNT1—osteoporosis	2.34e-05	0.00149	CbGpPWpGaD
Cevimeline—CHRM1—GPCR downstream signaling—PTHLH—osteoporosis	2.34e-05	0.00149	CbGpPWpGaD
Cevimeline—CHRM3—GPCR downstream signaling—PTHLH—osteoporosis	2.33e-05	0.00149	CbGpPWpGaD
Cevimeline—CHRM3—Metabolism—IDH2—osteoporosis	2.32e-05	0.00148	CbGpPWpGaD
Cevimeline—CHRM1—Signaling Pathways—MGLL—osteoporosis	2.29e-05	0.00146	CbGpPWpGaD
Cevimeline—CHRM3—Signaling Pathways—MGLL—osteoporosis	2.29e-05	0.00146	CbGpPWpGaD
Cevimeline—CYP2D6—Metabolism—FDPS—osteoporosis	2.27e-05	0.00145	CbGpPWpGaD
Cevimeline—CYP2D6—Metabolism—PKM—osteoporosis	2.27e-05	0.00145	CbGpPWpGaD
Cevimeline—CHRM1—Signaling Pathways—LRP5—osteoporosis	2.24e-05	0.00143	CbGpPWpGaD
Cevimeline—CHRM3—Signaling Pathways—LRP5—osteoporosis	2.23e-05	0.00142	CbGpPWpGaD
Cevimeline—CHRM3—Metabolism—CYP27A1—osteoporosis	2.18e-05	0.00139	CbGpPWpGaD
Cevimeline—CYP2D6—Metabolism—GPD2—osteoporosis	2.16e-05	0.00137	CbGpPWpGaD
Cevimeline—CYP2D6—Metabolism—PGLS—osteoporosis	2.16e-05	0.00137	CbGpPWpGaD
Cevimeline—CHRM1—Signaling Pathways—LRP6—osteoporosis	2.14e-05	0.00136	CbGpPWpGaD
Cevimeline—CHRM3—Signaling Pathways—LRP6—osteoporosis	2.13e-05	0.00136	CbGpPWpGaD
Cevimeline—CHRM1—Signaling by GPCR—PTHLH—osteoporosis	2.13e-05	0.00135	CbGpPWpGaD
Cevimeline—CHRM3—Metabolism—ACP5—osteoporosis	2.13e-05	0.00135	CbGpPWpGaD
Cevimeline—CHRM3—Signaling by GPCR—PTHLH—osteoporosis	2.12e-05	0.00135	CbGpPWpGaD
Cevimeline—CHRM1—GPCR downstream signaling—CALCA—osteoporosis	2.06e-05	0.00131	CbGpPWpGaD
Cevimeline—CHRM3—GPCR downstream signaling—CALCA—osteoporosis	2.05e-05	0.00131	CbGpPWpGaD
Cevimeline—CHRM3—Metabolism—TPI1—osteoporosis	1.98e-05	0.00126	CbGpPWpGaD
Cevimeline—CYP2D6—Metabolism—ATIC—osteoporosis	1.97e-05	0.00126	CbGpPWpGaD
Cevimeline—CYP2D6—Metabolism—PNP—osteoporosis	1.97e-05	0.00126	CbGpPWpGaD
Cevimeline—CHRM1—GPCR ligand binding—POMC—osteoporosis	1.91e-05	0.00122	CbGpPWpGaD
Cevimeline—CHRM3—GPCR ligand binding—POMC—osteoporosis	1.9e-05	0.00121	CbGpPWpGaD
Cevimeline—CHRM1—Signaling by GPCR—CALCA—osteoporosis	1.87e-05	0.00119	CbGpPWpGaD
Cevimeline—CHRM3—Signaling by GPCR—CALCA—osteoporosis	1.87e-05	0.00119	CbGpPWpGaD
Cevimeline—CHRM3—Metabolism—P4HB—osteoporosis	1.86e-05	0.00118	CbGpPWpGaD
Cevimeline—CHRM3—Metabolism—GAPDH—osteoporosis	1.82e-05	0.00116	CbGpPWpGaD
Cevimeline—CHRM1—Signaling Pathways—TLN1—osteoporosis	1.81e-05	0.00115	CbGpPWpGaD
Cevimeline—CHRM3—Signaling Pathways—TLN1—osteoporosis	1.8e-05	0.00115	CbGpPWpGaD
Cevimeline—CHRM3—Metabolism—RAP1A—osteoporosis	1.78e-05	0.00113	CbGpPWpGaD
Cevimeline—CYP2D6—Metabolism—OXCT1—osteoporosis	1.68e-05	0.00107	CbGpPWpGaD
Cevimeline—CYP2D6—Metabolism—CA2—osteoporosis	1.68e-05	0.00107	CbGpPWpGaD
Cevimeline—CYP2D6—Metabolism—MGLL—osteoporosis	1.63e-05	0.00104	CbGpPWpGaD
Cevimeline—CYP3A4—Biological oxidations—POMC—osteoporosis	1.58e-05	0.001	CbGpPWpGaD
Cevimeline—CHRM1—Signaling Pathways—P4HB—osteoporosis	1.56e-05	0.000993	CbGpPWpGaD
Cevimeline—CHRM3—Signaling Pathways—P4HB—osteoporosis	1.55e-05	0.00099	CbGpPWpGaD
Cevimeline—CHRM1—Circadian rythm related genes—IL6—osteoporosis	1.55e-05	0.000989	CbGpPWpGaD
Cevimeline—CHRM1—Signaling Pathways—PTH—osteoporosis	1.52e-05	0.000966	CbGpPWpGaD
Cevimeline—CHRM3—Signaling Pathways—PTH—osteoporosis	1.51e-05	0.000963	CbGpPWpGaD
Cevimeline—CHRM1—Signaling Pathways—RAP1A—osteoporosis	1.49e-05	0.000949	CbGpPWpGaD
Cevimeline—CYP3A4—Metabolism—PKM—osteoporosis	1.49e-05	0.000947	CbGpPWpGaD
Cevimeline—CYP3A4—Metabolism—FDPS—osteoporosis	1.49e-05	0.000947	CbGpPWpGaD
Cevimeline—CHRM3—Signaling Pathways—RAP1A—osteoporosis	1.48e-05	0.000946	CbGpPWpGaD
Cevimeline—CHRM1—Signaling Pathways—CNR2—osteoporosis	1.48e-05	0.000941	CbGpPWpGaD
Cevimeline—CHRM3—Signaling Pathways—CNR2—osteoporosis	1.47e-05	0.000938	CbGpPWpGaD
Cevimeline—CHRM1—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—osteoporosis	1.47e-05	0.000937	CbGpPWpGaD
Cevimeline—CHRM1—GPCR downstream signaling—ADCY5—osteoporosis	1.47e-05	0.000934	CbGpPWpGaD
Cevimeline—CHRM3—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—osteoporosis	1.47e-05	0.000934	CbGpPWpGaD
Cevimeline—CHRM3—GPCR downstream signaling—ADCY5—osteoporosis	1.46e-05	0.000931	CbGpPWpGaD
Cevimeline—CHRM1—Signaling Pathways—NFATC1—osteoporosis	1.45e-05	0.000926	CbGpPWpGaD
Cevimeline—CHRM3—Signaling Pathways—NFATC1—osteoporosis	1.45e-05	0.000923	CbGpPWpGaD
Cevimeline—CHRM1—Signaling Pathways—DKK1—osteoporosis	1.44e-05	0.000919	CbGpPWpGaD
Cevimeline—CHRM3—Signaling Pathways—DKK1—osteoporosis	1.44e-05	0.000916	CbGpPWpGaD
Cevimeline—CHRM3—Metabolism—ENO1—osteoporosis	1.44e-05	0.000915	CbGpPWpGaD
Cevimeline—CHRM3—Metabolism—PSMA5—osteoporosis	1.41e-05	0.000901	CbGpPWpGaD
Cevimeline—CHRM3—Metabolism—PSMA2—osteoporosis	1.41e-05	0.000901	CbGpPWpGaD
Cevimeline—CYP3A4—Metabolism—GPD2—osteoporosis	1.41e-05	0.000898	CbGpPWpGaD
Cevimeline—CYP3A4—Metabolism—PGLS—osteoporosis	1.41e-05	0.000898	CbGpPWpGaD
Cevimeline—CYP2D6—Metabolism—IDH2—osteoporosis	1.39e-05	0.000885	CbGpPWpGaD
Cevimeline—CHRM1—Signaling Pathways—WNT1—osteoporosis	1.39e-05	0.000885	CbGpPWpGaD
Cevimeline—CHRM3—Signaling Pathways—WNT1—osteoporosis	1.38e-05	0.000882	CbGpPWpGaD
Cevimeline—CHRM1—Signaling Pathways—FGA—osteoporosis	1.35e-05	0.000861	CbGpPWpGaD
Cevimeline—CHRM3—Signaling Pathways—FGA—osteoporosis	1.35e-05	0.000858	CbGpPWpGaD
Cevimeline—CHRM1—Signaling by GPCR—ADCY5—osteoporosis	1.33e-05	0.000848	CbGpPWpGaD
Cevimeline—CHRM3—Signaling by GPCR—ADCY5—osteoporosis	1.33e-05	0.000846	CbGpPWpGaD
Cevimeline—CYP2D6—Metabolism—CYP27A1—osteoporosis	1.31e-05	0.000832	CbGpPWpGaD
Cevimeline—CYP3A4—Metabolism—PNP—osteoporosis	1.29e-05	0.000821	CbGpPWpGaD
Cevimeline—CYP3A4—Metabolism—ATIC—osteoporosis	1.29e-05	0.000821	CbGpPWpGaD
Cevimeline—CYP2D6—Metabolism—ACP5—osteoporosis	1.27e-05	0.00081	CbGpPWpGaD
Cevimeline—CHRM1—Signaling Pathways—BMP2—osteoporosis	1.26e-05	0.0008	CbGpPWpGaD
Cevimeline—CHRM1—Signaling Pathways—PTHLH—osteoporosis	1.26e-05	0.0008	CbGpPWpGaD
Cevimeline—CHRM3—Signaling Pathways—BMP2—osteoporosis	1.25e-05	0.000798	CbGpPWpGaD
Cevimeline—CHRM3—Signaling Pathways—PTHLH—osteoporosis	1.25e-05	0.000798	CbGpPWpGaD
Cevimeline—CHRM1—Signaling Pathways—FGB—osteoporosis	1.23e-05	0.000783	CbGpPWpGaD
Cevimeline—CHRM3—Signaling Pathways—FGB—osteoporosis	1.23e-05	0.000781	CbGpPWpGaD
Cevimeline—CHRM1—Signaling Pathways—PSMA2—osteoporosis	1.19e-05	0.000756	CbGpPWpGaD
Cevimeline—CHRM1—Signaling Pathways—PSMA5—osteoporosis	1.19e-05	0.000756	CbGpPWpGaD
Cevimeline—CHRM3—Signaling Pathways—PSMA2—osteoporosis	1.18e-05	0.000754	CbGpPWpGaD
Cevimeline—CHRM3—Signaling Pathways—PSMA5—osteoporosis	1.18e-05	0.000754	CbGpPWpGaD
Cevimeline—CYP2D6—Metabolism—TPI1—osteoporosis	1.18e-05	0.000753	CbGpPWpGaD
Cevimeline—CHRM3—Metabolism—CYP19A1—osteoporosis	1.15e-05	0.000731	CbGpPWpGaD
Cevimeline—CYP2D6—Metabolism—P4HB—osteoporosis	1.11e-05	0.000708	CbGpPWpGaD
Cevimeline—CHRM1—Signaling Pathways—CALCA—osteoporosis	1.11e-05	0.000705	CbGpPWpGaD
Cevimeline—CHRM3—Signaling Pathways—CALCA—osteoporosis	1.1e-05	0.000702	CbGpPWpGaD
Cevimeline—CYP3A4—Metabolism—CA2—osteoporosis	1.1e-05	0.000698	CbGpPWpGaD
Cevimeline—CYP3A4—Metabolism—OXCT1—osteoporosis	1.1e-05	0.000698	CbGpPWpGaD
Cevimeline—CYP2D6—Metabolism—GAPDH—osteoporosis	1.09e-05	0.000695	CbGpPWpGaD
Cevimeline—CHRM1—GPCR downstream signaling—POMC—osteoporosis	1.08e-05	0.000687	CbGpPWpGaD
Cevimeline—CHRM3—GPCR downstream signaling—POMC—osteoporosis	1.08e-05	0.000685	CbGpPWpGaD
Cevimeline—CYP3A4—Metabolism—MGLL—osteoporosis	1.07e-05	0.000681	CbGpPWpGaD
Cevimeline—CYP2D6—Metabolism—RAP1A—osteoporosis	1.06e-05	0.000676	CbGpPWpGaD
Cevimeline—CHRM1—Signaling Pathways—KL—osteoporosis	1e-05	0.00064	CbGpPWpGaD
Cevimeline—CHRM3—Signaling Pathways—KL—osteoporosis	1e-05	0.000638	CbGpPWpGaD
Cevimeline—CHRM1—Signaling by GPCR—POMC—osteoporosis	9.79e-06	0.000624	CbGpPWpGaD
Cevimeline—CHRM3—Signaling by GPCR—POMC—osteoporosis	9.76e-06	0.000622	CbGpPWpGaD
Cevimeline—CHRM1—Signaling by GPCR—IL6R—osteoporosis	9.55e-06	0.000609	CbGpPWpGaD
Cevimeline—CHRM3—Signaling by GPCR—IL6R—osteoporosis	9.52e-06	0.000607	CbGpPWpGaD
Cevimeline—CHRM3—Metabolism—ADCY5—osteoporosis	9.38e-06	0.000597	CbGpPWpGaD
Cevimeline—CHRM3—Metabolism—GPX1—osteoporosis	9.35e-06	0.000595	CbGpPWpGaD
Cevimeline—CYP3A4—Metabolism—IDH2—osteoporosis	9.08e-06	0.000579	CbGpPWpGaD
Cevimeline—CHRM3—Metabolism—MTHFR—osteoporosis	8.62e-06	0.000549	CbGpPWpGaD
Cevimeline—CYP2D6—Metabolism—ENO1—osteoporosis	8.58e-06	0.000547	CbGpPWpGaD
Cevimeline—CYP3A4—Metabolism—CYP27A1—osteoporosis	8.54e-06	0.000544	CbGpPWpGaD
Cevimeline—CYP2D6—Metabolism—PSMA2—osteoporosis	8.46e-06	0.000539	CbGpPWpGaD
Cevimeline—CYP2D6—Metabolism—PSMA5—osteoporosis	8.46e-06	0.000539	CbGpPWpGaD
Cevimeline—CYP3A4—Metabolism—ACP5—osteoporosis	8.31e-06	0.000529	CbGpPWpGaD
Cevimeline—CHRM1—Signaling Pathways—ADCY5—osteoporosis	7.87e-06	0.000501	CbGpPWpGaD
Cevimeline—CHRM3—Signaling Pathways—ADCY5—osteoporosis	7.84e-06	0.0005	CbGpPWpGaD
Cevimeline—CYP3A4—Metabolism—TPI1—osteoporosis	7.72e-06	0.000492	CbGpPWpGaD
Cevimeline—CHRM1—Signaling Pathways—SPP1—osteoporosis	7.61e-06	0.000485	CbGpPWpGaD
Cevimeline—CHRM3—Signaling Pathways—SPP1—osteoporosis	7.59e-06	0.000483	CbGpPWpGaD
Cevimeline—CYP3A4—Metabolism—P4HB—osteoporosis	7.26e-06	0.000463	CbGpPWpGaD
Cevimeline—CYP3A4—Metabolism—GAPDH—osteoporosis	7.13e-06	0.000454	CbGpPWpGaD
Cevimeline—CYP3A4—Metabolism—RAP1A—osteoporosis	6.94e-06	0.000442	CbGpPWpGaD
Cevimeline—CHRM3—Metabolism—POMC—osteoporosis	6.9e-06	0.000439	CbGpPWpGaD
Cevimeline—CHRM1—Signaling Pathways—IRS2—osteoporosis	6.88e-06	0.000438	CbGpPWpGaD
Cevimeline—CYP2D6—Metabolism—CYP19A1—osteoporosis	6.86e-06	0.000437	CbGpPWpGaD
Cevimeline—CHRM3—Signaling Pathways—IRS2—osteoporosis	6.86e-06	0.000437	CbGpPWpGaD
Cevimeline—CHRM1—Signaling Pathways—LEP—osteoporosis	6.73e-06	0.000429	CbGpPWpGaD
Cevimeline—CHRM3—Signaling Pathways—LEP—osteoporosis	6.71e-06	0.000428	CbGpPWpGaD
Cevimeline—CHRM1—Signaling Pathways—ESR1—osteoporosis	6.43e-06	0.00041	CbGpPWpGaD
Cevimeline—CHRM3—Signaling Pathways—ESR1—osteoporosis	6.41e-06	0.000408	CbGpPWpGaD
Cevimeline—CHRM1—Signaling Pathways—IRS1—osteoporosis	6.01e-06	0.000383	CbGpPWpGaD
Cevimeline—CHRM3—Signaling Pathways—IRS1—osteoporosis	5.99e-06	0.000382	CbGpPWpGaD
Cevimeline—CHRM1—Signaling Pathways—POMC—osteoporosis	5.79e-06	0.000369	CbGpPWpGaD
Cevimeline—CHRM3—Signaling Pathways—POMC—osteoporosis	5.77e-06	0.000367	CbGpPWpGaD
Cevimeline—CHRM1—Signaling Pathways—IL6R—osteoporosis	5.64e-06	0.00036	CbGpPWpGaD
Cevimeline—CHRM3—Signaling Pathways—IL6R—osteoporosis	5.63e-06	0.000358	CbGpPWpGaD
Cevimeline—CYP3A4—Metabolism—ENO1—osteoporosis	5.61e-06	0.000358	CbGpPWpGaD
Cevimeline—CYP2D6—Metabolism—ADCY5—osteoporosis	5.61e-06	0.000357	CbGpPWpGaD
Cevimeline—CYP2D6—Metabolism—GPX1—osteoporosis	5.59e-06	0.000356	CbGpPWpGaD
Cevimeline—CHRM1—Signaling Pathways—IGF1—osteoporosis	5.57e-06	0.000355	CbGpPWpGaD
Cevimeline—CHRM3—Signaling Pathways—IGF1—osteoporosis	5.55e-06	0.000353	CbGpPWpGaD
Cevimeline—CYP3A4—Metabolism—PSMA2—osteoporosis	5.53e-06	0.000352	CbGpPWpGaD
Cevimeline—CYP3A4—Metabolism—PSMA5—osteoporosis	5.53e-06	0.000352	CbGpPWpGaD
Cevimeline—CYP2D6—Metabolism—MTHFR—osteoporosis	5.16e-06	0.000329	CbGpPWpGaD
Cevimeline—CYP3A4—Metabolism—CYP19A1—osteoporosis	4.49e-06	0.000286	CbGpPWpGaD
Cevimeline—CHRM1—Signaling by GPCR—IL6—osteoporosis	4.26e-06	0.000271	CbGpPWpGaD
Cevimeline—CHRM3—Signaling by GPCR—IL6—osteoporosis	4.24e-06	0.00027	CbGpPWpGaD
Cevimeline—CYP2D6—Metabolism—POMC—osteoporosis	4.12e-06	0.000263	CbGpPWpGaD
Cevimeline—CYP3A4—Metabolism—ADCY5—osteoporosis	3.67e-06	0.000234	CbGpPWpGaD
Cevimeline—CYP3A4—Metabolism—GPX1—osteoporosis	3.65e-06	0.000233	CbGpPWpGaD
Cevimeline—CYP3A4—Metabolism—MTHFR—osteoporosis	3.37e-06	0.000215	CbGpPWpGaD
Cevimeline—CHRM1—Signaling Pathways—MYC—osteoporosis	3.34e-06	0.000213	CbGpPWpGaD
Cevimeline—CHRM1—Signaling Pathways—TGFB1—osteoporosis	3.34e-06	0.000213	CbGpPWpGaD
Cevimeline—CHRM3—Signaling Pathways—MYC—osteoporosis	3.33e-06	0.000212	CbGpPWpGaD
Cevimeline—CHRM3—Signaling Pathways—TGFB1—osteoporosis	3.33e-06	0.000212	CbGpPWpGaD
Cevimeline—CYP3A4—Metabolism—POMC—osteoporosis	2.7e-06	0.000172	CbGpPWpGaD
Cevimeline—CHRM1—Signaling Pathways—IL6—osteoporosis	2.51e-06	0.00016	CbGpPWpGaD
Cevimeline—CHRM3—Signaling Pathways—IL6—osteoporosis	2.51e-06	0.00016	CbGpPWpGaD
